Therefore, the heterogeneity of androgen action within the different breast cancer subtypes has driven the chance to exploit specific AR signalling pathway(s) for successful therapeutic interventions in ongoing clinical trials, employing both AR agonists and antagonists for the treatment of different cohorts of breast cancer patients (Table 1) [41]. This evidence concerns the gene AR and breast carcinoma.